Neogen (NEOG) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
2 Feb, 2026Executive summary
Integration of 3M Food Safety products and services is nearly complete, with Petrifilm ramping up to full production and major milestones achieved, including relocation of sample handling lines and resolution of distribution inefficiencies.
Shipping and distribution challenges from integration have been resolved, and backlog levels are now reasonable, allowing a shift in focus to demand generation and operational efficiency for FY2025.
Food production volumes remained down year-over-year, but end market environment stabilized in Q4, with expectations for gradual improvement as food inflation eases.
Innovation and product launches, such as the USDA endorsement of the Molecular Detection System and the Petrifilm Automated Feeder, are expected to drive future growth.
End-market demand is stable but soft, with commercial focus shifting to demand generation.
Financial highlights
Q4 FY24 revenue was $237 million, down 2.1% year-over-year; core revenue grew 2% year-over-year.
Food Safety segment Q4 revenue was $167 million, down 1% year-over-year, with core growth of 4.3% led by Petrifilm and Pathogen Detection.
Animal Safety segment Q4 revenue was $70 million, with a 3.3% core revenue decline, mainly due to U.S. genomics.
Q4 gross margin was 47.9%, down from 50.9% a year ago; adjusted EBITDA was $53 million (22.4% margin), down from $63.1 million (26.1% margin) last year.
Adjusted net income was $22.4 million and adjusted EPS was $0.10, both down from prior year due to lower EBITDA.
Outlook and guidance
Fiscal 2025 revenue expected between $925 million and $955 million, with mid-single-digit core growth and margin expansion of ~100 basis points.
Adjusted EBITDA guidance for FY25 is $215–$235 million; capital expenditures projected at $85 million, with $55 million for integration.
Free cash flow expected to be strongly positive as CapEx and working capital investment decrease.
First half of FY25 anticipated to be lighter due to ongoing recovery from shipment constraints, with stronger growth in the second half.
Latest events from Neogen
- Integration nears completion as innovation and global expansion drive strong growth prospects.NEOG
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Operational recovery and integration progress set the stage for growth and margin expansion.NEOG
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q1 revenue and margins fell, but guidance and integration priorities remain intact.NEOG
Q1 202519 Jan 2026 - Raised FY2026 outlook and turnaround strategy drive confidence in growth and innovation.NEOG
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Q2 revenue hit $230M, integration advances, and international growth accelerates.NEOG
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Goodwill impairment drives $456M net loss despite core growth and margin actions.NEOG
Q2 202510 Jan 2026 - Integration progress and innovation drive growth amid regulatory momentum and portfolio actions.NEOG
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q2 FY26 delivered 2.9% core growth, margin gains, and raised guidance amid ongoing headwinds.NEOG
Q2 20268 Jan 2026 - Q3 revenue fell 3% and a $461M impairment led to a net loss and lower FY25 guidance.NEOG
Q3 202524 Dec 2025